AMRC Response: OSTP Request for Information – Accelerating the American Scientific Enterprise
The Association of Multisite Research Corporations (AMRC) appreciates the opportunity to comment on this important Federal policy update on accelerating the American scientific enterprise. AMRC applauds any initiative to advance science and clinical trials to the benefit of patients.
Collaboration over competition: Rovia’s CEO on the future of clinical research
Patricio brings over 20 years of leadership experience in healthcare across various sectors including pharma, med device, value-based primary care, hospital, pharmacy, and DME. He earned a B.S. in Biology from Duke University and an M.B.A from Stanford University. He’s an alum of Eli Lilly, and Johnson & Johnson, where his passion for medical innovation first took root.
From community practices to global scale: Pratia expands early-phase oncology research in the U.S.
Pratia LLC, part of Humaneva Group, announced in December 2025 the acquisition of a majority stake in P1 Trials, a U.S.-based early-phase-community oncology clinical research network.
What AMRC leaders are preparing for in 2026
2026 marks the end of trial-and-error vendor models. Sponsors are consolidating relationships and choosing partners who can plan, scale, and deliver consistently across pipelines.
What’s coming in 2026? Predictions from AMRC leaders
Soothsayers like Nostradamus, Mother Shipton , and the Amazing Kreskin have a decidedly mixed record when it comes to predicting the future. Still, it’s an irresistible human impulse, especially as a year ends, to peer into the proverbial crystal ball in the hopes of seeing what’s coming down the road.
Clinical Research in 2026: From fragmentation to strategic infrastructure
By 2026, the clinical research industry will look markedly different. This won’t come from a single breakthrough, but because of a collective shift in how Sponsors, sites, and partners choose to work together. Across the Association of Multisite Research Corporations (AMRC) members, a clear message emerges: the era of experimentation is ending. The era of strategic choice has begun.
AMRC’s latest research demonstrates the gap between MCRC performance and industry perceptions of quality
The Association of Multisite Research Corporations (AMRC) today announced the addition of three new members,Rovia Clinical Research, K2 Medical Research, and Eximia, further expanding its representation of leading multisite research organizations across the United States and internationally.
Member Spotlight: Headlands to be Acquired by THL Partners, Signalling Growing Investor Confidence in the MCRC Model
AMRC founding member Headlands Research has announced its pending acquisition by THL Partners, marking an important moment for both the organization and the broader clinical trials sector. The deal reflects the rapidly rising interest of the investment community in the future of multisite clinical research corporations (MCRCs).
Member spotlight: Javara: How a Mistaken Job Title Led Jennifer Byrne to a Life in Clinical Research
Derailed a bit at first to discover she’d in fact been hired as a clinical researcher, Byrne realized quickly. “I had found my life’s work.” Or, perhaps more accurately, it found her. And over three decades on, she’s CEO of Javara, a founding member of the Association for Multisite Research Corporations (AMRC) and a leading voice in clinical trial innovation.
Member spotlight: Pratia on building the future of clinical trials through technology and diversity
The prospect of finding new cures for patients is what drives Mona Alqam and her team at Pratia, a Research Site Network with 90+ sites across eight countries. With 1500+ Clinical Trials carried out since 2012 across approximately 85% of all Therapeutic Areas and protocol designs, Pratia has engaged in a wide spectrum of clinical trial activities.
